This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Feb;52(2):296-304.

doi: 10.1016/j.jhep.2009.11.010. Epub 2009 Dec 16.

Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference

Jean-François Dufour¹, Philip Johnson

Affiliations

PMID: 20006399
DOI: 10.1016/j.jhep.2009.11.010

Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference

Jean-François Dufour et al. J Hepatol. 2010 Feb.

. 2010 Feb;52(2):296-304.

doi: 10.1016/j.jhep.2009.11.010. Epub 2009 Dec 16.

Authors

Jean-François Dufour¹, Philip Johnson

Affiliation

¹ Institute of Clinical Pharmacology and Visceral Research, University of Berne, Berne, Switzerland. jf.dufour@ikp.unibe.ch

PMID: 20006399
DOI: 10.1016/j.jhep.2009.11.010

No abstract available

PubMed Disclaimer

Similar articles

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Jelic S, Sotiropoulos GC; ESMO Guidelines Working Group. Jelic S, et al. Ann Oncol. 2010 May;21 Suppl 5:v59-64. doi: 10.1093/annonc/mdq166. Ann Oncol. 2010. PMID: 20555104 No abstract available.
Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A, Huynh TJ, Rajan DK, Marquez MA, Grant DR, Huynh DC, Jaskolka JD. Shuster A, et al. J Vasc Interv Radiol. 2013 Jun;24(6):805-12. doi: 10.1016/j.jvir.2013.01.499. Epub 2013 Apr 4. J Vasc Interv Radiol. 2013. PMID: 23562641 Clinical Trial.
[Hepatocellular carcinoma: what's new?].
Teufel A, Marquardt JU, Galle PR, Wörns M. Teufel A, et al. Dtsch Med Wochenschr. 2012 Feb;137(5):210-3. doi: 10.1055/s-0031-1292890. Epub 2012 Jan 16. Dtsch Med Wochenschr. 2012. PMID: 22250042 Review. German. No abstract available.
Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials?
Majno P, Giostra E, Mentha G. Majno P, et al. Liver Transpl. 2007 Nov;13(11 Suppl 2):S27-35. doi: 10.1002/lt.21328. Liver Transpl. 2007. PMID: 17969086 Review. No abstract available.
Hepatocellular carcinoma (primary cancer of the liver).
Barbare JC, Boige V, Boudjema K, Lescesne R, Trinchet JC. Barbare JC, et al. Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S57-2S61. Gastroenterol Clin Biol. 2006. PMID: 17151564 Review. No abstract available.

See all similar articles

Cited by

Screening the genome for HCC-specific CpG methylation signatures as biomarkers for diagnosis and prognosis evaluation.
Zhang RK, Liu JL. Zhang RK, et al. BMC Med Genomics. 2021 Jun 19;14(1):163. doi: 10.1186/s12920-021-01015-9. BMC Med Genomics. 2021. PMID: 34147096 Free PMC article.
Expression and prognostic potential of TMEM204: a pan-cancer analysis.
Zhen Z, Li M, Zhong M, Liu J, Huang W, Ye L. Zhen Z, et al. Int J Clin Exp Pathol. 2022 Jul 15;15(7):258-271. eCollection 2022. Int J Clin Exp Pathol. 2022. PMID: 35949807 Free PMC article.
The lncRNA MIR4435-2HG is upregulated in hepatocellular carcinoma and promotes cancer cell proliferation by upregulating miRNA-487a.
Kong Q, Liang C, Jin Y, Pan Y, Tong D, Kong Q, Zhou J. Kong Q, et al. Cell Mol Biol Lett. 2019 Apr 4;24:26. doi: 10.1186/s11658-019-0148-y. eCollection 2019. Cell Mol Biol Lett. 2019. PMID: 30988676 Free PMC article.
Individualized medicine 2010.
Blum HE. Blum HE. J Cell Mol Med. 2010 Sep;14(9):2257-63. doi: 10.1111/j.1582-4934.2010.01155.x. J Cell Mol Med. 2010. PMID: 20731747 Free PMC article.
Study on the mechanism of LOXL1-AS1/miR-3614-5p/YY1 signal axis in the malignant phenotype regulation of hepatocellular carcinoma.
Feng Z, Ye Z, Xie J, Chen W, Li W, Xing C. Feng Z, et al. Biol Direct. 2021 Dec 4;16(1):24. doi: 10.1186/s13062-021-00312-8. Biol Direct. 2021. PMID: 34863279 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information